Isabelle Xavier de-Britto, Stephanie Nascimento Neves-da-Silva, Luciana Magalhaes Rebelo Alencar, Pierre Basilio Almeida Fechine, Ralph Santos-Oliveira
{"title":"The [18F] F-PSMA Probe: Chemical Perspectives.","authors":"Isabelle Xavier de-Britto, Stephanie Nascimento Neves-da-Silva, Luciana Magalhaes Rebelo Alencar, Pierre Basilio Almeida Fechine, Ralph Santos-Oliveira","doi":"10.2174/0109298673333642250102080759","DOIUrl":null,"url":null,"abstract":"<p><p>This study discusses the chemical perspectives of the [18F]F-PSMA probe, a pivotal tool in prostate cancer imaging. [18F]Fluorine, a positron emitter with a half-life of 109.8 minutes, is produced in a cyclotron by bombarding [18O]-enriched targets with protons. The chemistry of this isotope parallels that of stable fluorine, facilitating its use in positron emission tomography (PET). The synthesis of [18F]F-PSMA involves a nucleophilic substitution (SN1) reaction, where [18F]fluoride ion replaces a leaving group in the precursor molecule. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer cells, making it a crucial target for imaging. PSMA-targeted radioligands, such as [68Ga]Ga-PSMA-11, [18F]F-DCFPyL, and [99mTc]Tc-PSMA-I&S, bind to the extracellular domain of PSMA, enabling precise imaging. The design of PSMA radiotracers incorporates specific targeting moieties, functional groups for radiolabeling, and linkers to maintain binding affinity and pharmacokinetics. Common linkers include aliphatic, aromatic, peptide-based, and polyethylene glycol structures, while functional groups like tosylate and PyTFP are used for efficient [18F]fluorination. This review aims to elucidate the main linker and reactions in order to optimize these components to improve imaging sensitivity and specificity in detecting prostate cancer.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673333642250102080759","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study discusses the chemical perspectives of the [18F]F-PSMA probe, a pivotal tool in prostate cancer imaging. [18F]Fluorine, a positron emitter with a half-life of 109.8 minutes, is produced in a cyclotron by bombarding [18O]-enriched targets with protons. The chemistry of this isotope parallels that of stable fluorine, facilitating its use in positron emission tomography (PET). The synthesis of [18F]F-PSMA involves a nucleophilic substitution (SN1) reaction, where [18F]fluoride ion replaces a leaving group in the precursor molecule. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer cells, making it a crucial target for imaging. PSMA-targeted radioligands, such as [68Ga]Ga-PSMA-11, [18F]F-DCFPyL, and [99mTc]Tc-PSMA-I&S, bind to the extracellular domain of PSMA, enabling precise imaging. The design of PSMA radiotracers incorporates specific targeting moieties, functional groups for radiolabeling, and linkers to maintain binding affinity and pharmacokinetics. Common linkers include aliphatic, aromatic, peptide-based, and polyethylene glycol structures, while functional groups like tosylate and PyTFP are used for efficient [18F]fluorination. This review aims to elucidate the main linker and reactions in order to optimize these components to improve imaging sensitivity and specificity in detecting prostate cancer.
期刊介绍:
Aims & Scope
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.